Pyoderma gangrenosum associated with ulcerative colitis: A recalcitrant case responded to adalimumab with granulocyte and monocyte adsorption apheresis

J Dermatol. 2020 May;47(5):e213-e215. doi: 10.1111/1346-8138.15303. Epub 2020 Mar 11.

Authors

Yuki Isami¹, Yuriko Kawase¹, Akari Kondo¹, Wataru Akita², Koji Yasuda³, Takeshi Matsutani⁴, Hiroshi Mitsui¹

Affiliations

¹ Department of Dermatology, The Fraternity Memorial Hospital, Tokyo, Japan.
² Department of Nephrology, The Fraternity Memorial Hospital, Tokyo, Japan.
³ Department of Surgery, The Fraternity Memorial Hospital, Tokyo, Japan.
⁴ Department of Gastroenterology, The Fraternity Memorial Hospital, Tokyo, Japan.

PMID: 32162361
DOI: 10.1111/1346-8138.15303

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / administration & dosage*
Blood Component Removal / methods*
Colitis, Ulcerative / complications
Colitis, Ulcerative / diagnosis*
Colitis, Ulcerative / immunology
Colitis, Ulcerative / therapy
Colonoscopy
Combined Modality Therapy / methods
Female
Granulocytes / immunology
Humans
Infliximab / administration & dosage
Middle Aged
Monocytes / immunology
Pyoderma Gangrenosum / immunology
Pyoderma Gangrenosum / therapy*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / immunology

Substances

TNF protein, human
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab